Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Acquires Rights to Predictive Genes for Bladder Cancer from AROS

NEW YORK (GenomeWeb News) - Stratagene said today that it has acquired an exclusive licensing option to a family of patents related to bladder cancer owned by Denmark’s AROS Applied Biotechnology.
 
Under the agreement, Stratagene has the right to evaluate and exclusively license the rights to certain gene groups that have predictive capabilities for bladder cancer.
 
The agreement expands Stratagene’s molecular diagnostics intellectual property portfolio. The company said it will use the patents to develop Strategene-branded test kits and products.
 

Financial details were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.